Triomune

Triomune Tablets Prices (Stavudine 30 mg + Lamivudine 150 mg + Nevirapine 200 mg)
30 tablets of Triomune 30 (Stavudine 30 mg + Lamivudine 150 mg + Nevirapine 200 mg)	US$60.00
60 tablets of Triomune 30 (Stavudine 30 mg + Lamivudine 150 mg + Nevirapine 200 mg)	US$118.00
90 tablets of Triomune 30 (Stavudine 30 mg + Lamivudine 150 mg + Nevirapine 200 mg)	US$174.00

Triomune Tablets Prices (Stavudine 40 mg + Lamivudine 150 mg + Nevirapine 200 mg)
30 tablets of Triomune 40 (Stavudine 40 mg + Lamivudine 150 mg + Nevirapine 200 mg)	US$66.00
60 tablets of Triomune 40 (Stavudine 40 mg + Lamivudine 150 mg + Nevirapine 200 mg)	US$130.00
90 tablets of Triomune 40 (Stavudine 40 mg + Lamivudine 150 mg + Nevirapine 200 mg)	US$192.00

Composition

Description

Triomune is a combination of 3 drugs commonly used in the management of Human Immunodeficiency Virus (HIV) infection. Both stavudine and lamivudine belong to the nucleoside analogue class of antiretroviral drugs. Both drugs act by terminating the growth of the DNA chain and inhibiting the reverse transcriptase of HIV. Nevirapine is a non-nucleoside reverse transcriptase inhibitor. It acts by directly inhibiting reverse transcriptase.

Studies using the combination of stavudine + lamivudine + nevirapine have demonstrated its efficacy in patients with HIV infection. In the study presented by Kaspar et al at the 5th Conference on Retroviruses and Opportunistic Infections, Chicago 1998, 87% of patients had undetectable viral loads at 33-44 weeks. In the study presented by Russell et al at the 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon 1999, CD4 counts increased by 195 cells/mm3 and 230 cells/mm3 in patients with low (<80,000 copies/ml) and high viral load (>80,000 copies/ml) groups, respectively at the end of 1 year. 72% of patients with low viral loads and 80% of patients with high viral loads had undetectable viral loads at the end of 1 year.

Each tablet of Triomune contains half of the commonly prescribed daily doses of stavudine, lamivudine and nevirapine. All three drugs are to be administered twice daily, permitting a fixed-dose combination to be formulated. With the availability of this combination formulation, patients may be better able to adhere to triple drug regimens, thereby enhancing compliance.

Indications

Triomune is indicated for the treatment of HIV infection, once patients have been stabilized on the maintenance regimen of nevirapine 200 mg bd, and have demonstrated adequate tolerability to nevirapine.

Dosage and Administration

• Triomune 30: 1 tablet twice daily for patients weighing < 60 kg
• Triomune 40: 1 tablet twice daily for patients weighing > 60 kg